AXIMOTCPharmaceutical PreparationsFiscal year ends December 31
AXIM BIOTECHNOLOGIES, INC.
Financials through Q2 FY2024, quarter ended Jun 30, 2024Last filing: 10-Q on Aug 19, 2024
$0.00+0.00 (+2.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Axim Biotechnologies has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Axim Biotechnologies filed with the SEC
AXIM ® Biotechnologies Signs Commercialization Agreement W ith Leading Healthcare Solutions Company for Global Distribution , Sales of Ophthalmic Diagnostics Solutions
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
AXIM Biotech Launches For Research Use Only Sales for it s COVID-19 Neutralizing Antibody Test
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K